Posted by Michael Wonder on 26 Nov 2025
FDA approves a new treatment for primary immunoglobulin A nephropathy
25 November 2025 - The US FDA has granted accelerated approval to Voyxact (sibeprenlimab-szsi) injection to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.
The efficacy and safety of Voyxact were evaluated in a randomised, double-blind, placebo-controlled trial in adults with biopsy-confirmed immunoglobulin A nephropathy.
